Insulin-like growth factor binding protein (IGFBP)-3 has both growth-inhibiting and growthpromoting effects at the cellular level. The cytotoxic action of several anticancer drugs is linked to increased ceramide generation through sphingomyelin hydrolysis or de novo biosynthesis. Herein, we investigated the role of IGFBP-3 on apoptosis of human umbilical vein endothelial cells (HUVEC) and its relationship with ceramide levels. We report that IGFBP-3 exerts dual effects on HUVEC, potentiating doxorubicin-induced apoptosis but enhancing survival in serumstarved conditions. Ceramide was increased by IGFBP-3 in the presence of doxorubicin and decreased when IGFBP-3 was added alone to cells cultured in serum-free medium. The protection exerted by the ceramide synthase inhibitor fumonisin B1 over doxorubicin-induced apoptosis was enhanced by IGFBP-3 with concomitant reduction of ceramide levels. IGFBP-3 alone activated sphingosine kinase (SK) and increased SK1 mRNA; the SK inhibitor N,Ndimethylsphingosine (DMS) blocked IGFBP-3 antiapoptotic effect. Moreover, IGFBP-3 increased IGF-I mRNA and dramatically enhanced IGF-I release. IGF-I receptor (IGF-IR) and its downstream signaling pathways Akt and ERK were phosphorylated by IGFBP-3, whereas inhibition of IGF-IR phosphorylation with tyrphostin AG1024 suppressed the antiapopoptic effect of IGFBP-3. Finally, IGFBP-3 increased endothelial cell motility in all experimental conditions. These findings provide evidence that IGFBP-3 differentially regulates endothelial cell apoptosis by involvement of the sphingolipid signaling pathways. Moreover, the survival effect of IGFBP-3 seems to be mediated by the IGF-IR. IGFBP-3 is a member of a family of high affinity binding proteins that regulate the function of insulin-like growth factors (IGFs) through modulating their interaction with the specific tyrosine kinase receptor (IGF-IR) (3). In addition to the IGF-dependent functions, IGFBP-3 exerts direct IGF-independent effects by inhibiting proliferation, stimulating apoptosis, and enhancing the effect of apoptotic agents in a variety of cell types. However, the cellular mechanisms of IGFBP-3 action have not been fully elucidated (4).
IGFBP-3 is a member of a family of high affinity binding proteins that regulate the function of insulin-like growth factors (IGFs) through modulating their interaction with the specific tyrosine kinase receptor (IGF-IR) (3) . In addition to the IGF-dependent functions, IGFBP-3 exerts direct IGF-independent effects by inhibiting proliferation, stimulating apoptosis, and enhancing the effect of apoptotic agents in a variety of cell types. However, the cellular mechanisms of IGFBP-3 action have not been fully elucidated (4) .
We have shown that exogenous IGFBP-3 potentiates the effect of doxorubicin over cardiac cell apoptosis and that endogenous IGFBP-3 mediates doxorubicin-induced apoptosis in cardiomyocytes (5) . Many stress stimuli induce apoptosis in various cell types by increasing ceramide, a key mediator in apoptotic signaling. Ceramide generation may result from sphingomyelin hydrolysis by various sphingomyelinases or by de novo synthesis through activation of serine palmitoyl transferase (SPT) or ceramide synthase (6) . The anthracycline daunorubicin has been shown to induce ceramide-mediated apoptosis, via activation of ceramide synthase (7) .
The aim of the present study was to define the role of IGFBP-3 on HUVEC apoptosis and survival. Moreover, we wished to investigate the involvement of sphingolipid signaling in mediating IGFBP-3 effects on endothelial cell fate.
The results of this study show for the first time that IGFBP-3 exerts dual effects on HUVEC, enhancing apoptosis induced by doxorubicin and exerting antiapoptotic action in serum-starved cells. IGFBP-3 action is mediated by ceramide through de novo synthesis, as demonstrated by experiments using the specific inhibitor of ceramide synthase fumonisin B1. Furthermore, IGFBP-3 exerted its antiapoptotic effect by activating SK to produce sphingosine-1-phosphate (S1P) and by increasing SK1 mRNA. IGFBP-3 even up-regulated IGF-I expression and activated IGF-IR as well as the downstream phosphatidyl inositol-3 kinase (PI3K), Akt, and mitogenactivated protein kinase (MAPK) extracellular signal-regulated kinase (ERK)1/2 signaling pathways. Moreover, cell motility was increased by IGFBP-3, suggesting its possible involvement in the angiogenic process. These findings provide evidence for a novel role of IGFBP-3 on modulating apoptosis and survival of primary human endothelial cells through mechanisms that involve the sphingolipid signaling pathways.
MATERIAL AND METHODS

Reagents
Nonglycosylated rhIGFBP-3 and rhIGF-I were from IBT-Immunological and Biochemical Testsystems GmbH (Reutlingen, Germany). Doxorubicin was from Pharmacia and Upjohn (Milan, Italy). M199, fetal bovine serum, penicillin and streptomycin were from GIBCO BRL Invitrogen Corp. (S. Giuliano Milanese, Milan, Italy). MTT and fibroblast growth factor were from ICN Biochemicals, Inc. (Aurora, OH, USA). Fumonisin B1, HOECHST 33258, protein Asepharose and propidium iodide were from Sigma-Aldrich (Milan, Italy). D-erythro-sphingosine was from Biomol Research Laboratory, Inc. (DBA, Italy). Ceramide from porcine brain, used for internal standard, N,N-dimethylsphingosine (DMS), and S1P were from Avanti Polar Lipids Inc. (Alabaster, AL). [ 32 P]ATP and NEL Chemiluminescence Reagent Plus were from Perkin Elmer Life Sciences, Inc. (Boston, MA). IGF-IR β subunit, ERK1, Akt1/2 antibodies were from Santa
FACS analysis of apoptosis
Cells harvested by PBS/EDTA were pooled with cells of the conditioned medium and fixed in 100% ethanol for 24 h before analysis. After three washes in PBS, cells were resuspended in a reaction buffer (0.05 mg/ml propidium iodide, 0.1% sodium citrate, 0.02 mg/ml RNase A, 0.3% Nonidet P-40, pH 8.3) and incubated overnight at 4°C before measurement by FacScan (Becton Dickinson, San Jose CA, USA). Apoptotic cells were shown as a hypodiploid peak.
Hoechst staining of apoptotic cells
Morphological changes in the nuclear chromatin of apoptotic cells were detected by Hoechst 33258 staining. Cells harvested by trypsin were pooled with the cells from conditioned medium, fixed with 4% formaldehyde in PBS for 15 min at 4°C, washed, resuspended in 70% ethanol and stored at -20°C until use. HUVEC were then washed twice in PBS and stained in 50 µl of PBS containing 10 µg/ml Hoechst 33258. Following 15 min incubation at room temperature, a 15 µl aliquot was placed on a glass slide, and 500 stained nuclei were double counted under a fluorescence microscope.
Quantification of endogenous ceramide
Total endogenous ceramide level was measured using the diacylglycerol kinase assay (DGK) as described previously (10) . HUVEC were collected together with cells in conditioned medium and lipids extracted according to Bligh and Dyer (11) . The organic phase was divided in 1/2 and 1/6 aliquots, dried and used for ceramide measurement and total phospholipid measurement, respectively. Briefly, 30 nmol of extracted lipids were incubated at room temperature for 45 min in the presence of β-octylglucoside/dioleoylphosphatidylglycerol micelles, 2 mM dithiothreitol, 5 µg of proteins of DGK containing membranes and 1 mM ATP (mixed with [γ-P 32 ]ATP at a final radioactivity of 13 µCi/ml) in a final volume of 0.1 ml. At the end of reaction, lipids were extracted according to Bligh and Dyer. [ 32 P]ceramide-1-phosphate was determined by TLC separation in chloroform/acetone/methanol/acetic acid/water (10/4/3/2/1, by volume) and visualization by autoradiography, followed by scraping the radioactive ceramide-1-phosphate spots and counting in a scintillator counter. Ceramide level referred to the level of total phospholipids.
SK activity assay
Cells were washed in ice-cold PBS, scraped from the culture dishes and homogenized in lysis buffer (20mM Tris pH 7.4, 20% glycerol, 1 mM EDTA, 1 mM dithiothreitol, 10 µM MgCl 2 , Na 3 Vo 4 , 15 mM NaF, 10 µg/µl leupeptin and aprotinin and 1 mM phenylmethylsulfonyl fluoride). After ultracentrifugation at 100,000 × g for 60 min, the protein concentration was determined from the cytosolic fractions of the supernatants (Coomassie Plus TM Protein Assay Kit, Pierce, IL). Equal amounts of protein were then incubated with 10 µM D-erythrosphingosine dissolved in 0.1% Triton X-100 [γ 32 ]ATP (1 mM, 10 µCi dissolved in 10 mM MgCl 2 ) for 30 min at 37°C. The reaction was stopped by the addition of 800 µl of chloroform/methanol/HCl (100:200:1). After addition of 200 µl chloroform and 200 µl KCl, the samples were centrifuged at 3000 g for 5 min. The organic layer was dried down in a speed vac and resuspended in chloroform/methanol/HCl (100:200:1). Lipids were resolved on silica TLC plates (Whatmann), using 1-butanol/methanol/acetic acid/water (8:2:1:2) as a solvent system. Labeled S1P was visualized by autoradiography and quantitated by scraping the radioactive S1P spots and counting in a scintillator counter. The enzyme activity was normalized by total protein concentration of each sample.
RT-PCR
Total RNA extraction from HUVEC and reversed transcription to cDNA from 3 µg RNA, were performed as described (5) . The primer sequences (12) , adapted to human SK1 mRNA (accession number BC008040), were Fwd: 5′-GGTGGTCATGTCTGGAGACG-3′; Rev: 5′-GCAATAGCGTGCAGTTGGTCAG-3′. Primers for human β-actin (accession number NM_001101) were Fwd: 5′-GGTCATCTTCTCGCGGTTGGCCTTGGGGT-3′, Rev: 5′-CCCCAGGCACCAGGGCGTGAT-3′. Primers for human IGF-I (accession number X56774 S61860) were Fwd: 5′-GCTGGTGGATGCTCTTCA-3′; Rev: 5′-CTGACTTGGCAGGCTTGA-3′, as described previously (13) . 10 µl cDNA were amplified by PCR in a 50 µl volume. After one initial denaturation step (95°C for 8 min), 29 cycles for SK1 and 36 cycles for IGF-I were performed (1 cycle: 30 s at 94°C, 30 s at 60°C for SK1 and 30 s at 57°C for IGF-I, 1 min at 72°C) followed by elongation for 7 min at 72°C. The PCR products (200 bp for SK1, 230 bp for β-actin, 182 bp for IGF-I) were separated by 1.5% agarose gel electrophoresis and visualized by ethidium bromide staining.
IGF-IR immunoprecipitation
Cells were scraped in ice-cold RIPA lysis buffer (Mammalian Cell Lysis Kit, Sigma), according to the manufacturer's instructions. Specific protease inhibitors were added to the lysis buffer (1 mM Na 3 VO 4 , 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride). After centrifugation at 14,000 × g for 10 min, the supernatants were incubated overnight at 4°C with anti-IGF-IR β antibody (1:500 dilution). Immune complexes were precipitated by adding protein A-sepharose and incubating for 2 h at 4°C. The pellet was resuspended in 40 µl of reducing Laemmli buffer and the proteins separated by 8% gel SDS-PAGE.
Western immunoblot
Proteins for Akt and ERK immunoblots were resolved in 12% SDS-PAGE. All proteins were transferred to a nitrocellulose membrane; after blocking with 1% BSA in Tris-buffered saline with 0.1% Tween for 2 h at room temperature, membranes were incubated overnight at 4°C with one of the specific antibody (P-tyrosine and IGF-IR for immunoprecipitates; P-Akt, Akt, P-ERK, and ERK for other proteins) (1:500 or 1:1000 dilutions). The immunoreactive proteins were visualized using horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit (1:5000) by enhanced chemiluminescence.
Detection of IGF-I in conditioned medium
IGF-I was measured by radioimmunoassay (SM-C-RIA-CT kit, BioSource Europe, Nivelles, Belgium) in 20-fold concentrated medium of subconfluent HUVEC plated in 100-mm dish. To avoid interference from IGFBPs, all samples were treated with acid-ethanol according to the manufacturer's instructions.
In vitro cell migration
Cell migration in subconfluent HUVEC plated in 100 mm dish was studied over a period of 16 h under a Nikon Diaphot-inverted microscope with a X20 phase-contrast objective in an attached, hermetically sealed Plexiglas Nikon NP-2 incubator at 37°C, as described previously (14) . Migration of at least 30 cells was analyzed for each experimental condition.
Statistics
Data are presented as mean ± SE. Statistical analysis was performed using ANOVA. Significance was established when P < 0.05.
RESULTS
IGFBP-3 enhances the apoptotic effect of doxorubicin and reduces apoptosis induced by serum starvation
Previous studies have shown that both doxorubicin and serum deprivation induce apoptosis in HUVEC (15, 16) . To investigate whether IGFBP-3 exerts an effect on apoptosis induced by doxorubicin and serum starvation, subconfluent HUVEC were preincubated for 1 h with 1000 ng/ml IGFBP-3 in serum-free medium and subsequently cultured with or without 0.5 µM doxorubicin for 24 h. Figure 1A shows that cell viability in serum-deprived cells was ≈2.7 fold decreased compared with cells grown in the presence of serum. Under serum deprivation, IGFBP-3 had a protective effect, significantly increasing HUVEC viability. Endothelial cell survival was reduced by doxorubicin compared with serum-free medium and IGFBP-3 significantly enhanced doxorubicin-induced cell death. Apoptosis was assessed by flow cytometry and by Hoechst 33258 staining. In serum-free conditions IGFBP-3 reduced the percentage of apoptotic cells in the pre-G 1 phase and increased apoptosis induced by doxorubicin (Fig. 1B) ; the number of cells that showed typical apoptotic chromatin condensation and nuclear fragmentation was significantly reduced by IGFBP-3 upon serum deprivation and increased after addition of doxorubicin ( Fig. 1C and D) .
To exclude that the survival effect of IGFBP-3 may be the result of adding exogenous protein to the cells, 0.1% bovine serum albumin (BSA) was added to HUVEC in serum-free medium. Cell survival by MTT (Fig. 1A) and apoptosis by Hoechst and FACS analysis (data not shown) were assessed after 24 h, showing no significant differences between serum-free medium alone and with addition of BSA. These results indicate that in human endothelial cells IGFBP-3 induces dual effects on apoptosis triggered by different stimuli.
IGFBP-3 potentiates the fumonisin B1 reversal of doxorubicin-induced cell death and apoptosis
Ceramide is a key mediator of cell stress and apoptosis that can be generated by sphingomyelin hydrolysis or by de novo synthesis (6) . On the basis of previous studies showing that doxorubicin and other chemotherapeutic drugs induce apoptosis through de novo ceramide synthesis (7, 17) , we aimed to investigate whether IGFBP-3 may be involved in this pathway. De novo ceramide synthesis is mediated by the key enzyme ceramide synthase that can be potently and specifically inhibited by the fungal metabolite fumonisin B1 (18) . Therefore, IGFBP-3 effect on endothelial cell apoptosis induced by serum deprivation and doxorubicin was studied in the presence of fumonisin B1. HUVEC were preincubated with IGFBP-3 (1000 ng/ml) for 1 h before addition of fumonisin B1 (100 µM) for 40 min and doxorubicin (0.5 µM). Cells were evaluated for viability and apoptosis after 24 h. Figure 2 shows that in serum-free conditions, fumonisin B1 had no significant effect on cell viability and apoptosis whereas IGFBP-3 increased cell survival and decreased apoptosis, not only alone but also in the presence of fumonisin B1. In doxorubicin-treated cells, fumonisin B1 significantly reduced cell death and apoptosis. Under these conditions, IGFBP-3 with fumonisin B1 further reduced cell death and apoptosis, whereas a proapoptotic effect had been exerted by IGFBP-3 in the absence of fumonisin B1. Lower concentrations of fumonisin B1 were also assayed (25 and 50 µM); at these concentrations, the effects induced by 100 µM were not observed (data not shown).
These results show that in HUVEC, fumonisin B1 acts as antagonist of apoptosis induced by doxorubicin, likely inhibiting the production of ceramide. IGFBP-3 increases apoptosis in cells treated with doxorubicin but displays an opposite, antiapoptotic effect in the presence of fumonisin B1. Thus IGFBP-3 may influence endothelial cell apoptosis through de novo pathway of ceramide synthesis.
IGFBP-3 reduces ceramide in serum-starved conditions and increases doxorubicin-induced ceramide levels
The previous results showed that IGFBP-3 differently affects apoptosis with or without the ceramide synthase inhibitor FB1. Therefore, it was of interest to determine the effect of IGFBP-3 on intracellular ceramide levels. Cells were treated for 24 h in serum-free medium in the presence or absence of IGFBP-3 (1000 ng/ml), doxorubicin (0.5 µM) and fumonisin B1 (100 µM); ceramide was quantified using the diacylglycerol kinase method. Ceramide levels were significantly increased in serum-starved cells compared with cells cultured in the presence of serum (data not shown). IGFBP-3 attenuated ceramide production in serum-free medium but further increased doxorubicin-induced ceramide levels (Fig. 3) . Fumonisin B1 decreased the production of ceramide in cells either with or without doxorubicin; in these conditions IGFBP-3, in the presence of the ceramide synthase inhibitor, further reduced ceramide levels. These results are in agreement with the experiments on apoptosis performed under the same conditions ( Fig.  2B and C) and suggest that IGFBP-3 may influence ceramide levels in endothelial cells.
IGFBP-3 stimulates SK activity and induces SK1 mRNA
Ceramide and sphingosine, the precursors of sphingosine-1-phopshate (S1P) are important regulatory components of apoptosis. In contrast, S1P has been implicated in cellular proliferation and survival (19) . On the basis of the sphingolipid rheostat concept, we sought to determine the effect of IGFBP-3 on SK activation. As shown in Fig. 4A , IGFBP-3 caused a rapid increase in SK activity in HUVEC, peaking at 30 min (≈230% compared with basal). IGFBP-3 effect was also analyzed for the expression of SK1, the SK isoform that stimulates cell growth and survival (19) . We found that IGFBP-3 significantly increased SK1 mRNA in a time-dependent manner, reaching ≈450% of control at 180 min (Fig. 4B ). The addition of the competitive inhibitor of SK, DMS (0.5 µM) completely blocked the IGFBP-3 antiapoptotic effect in serum deprived HUVEC after 24 h (Fig. 4C) , suggesting that IGFBP-3 reduces ceramide levels and exerts its protective effect likely by increasing S1P levels. Similar results were obtained for cell viability with the MTT assay (data not shown).
IGFBP-3 up-regulates IGF-I expression
Previous studies have shown that IGFBP-3 is able to either positively or negatively modulate IGF-I actions; moreover, IGFBP-3 intrinsic inhibitory or mitogenic activities are both dependent on and independent of binding to IGFs (4) . On the basis of the results showing that IGFBP-3 exerts antiapoptotic effects, decreasing ceramide and activating SK to increase S1P, we aimed to evaluate IGFBP-3 induction of IGF-I expression and release.
Cells in serum-free medium were treated either with or without IGFBP-3, fumonisin B1 and doxorubicin; secretion of IGF-I into cell conditioned medium was evaluated by radioimmunoassay. Low IGF-I levels did not change in the absence of IGFBP-3 at any condition, whereas in the presence of IGFBP-3, alone or with doxorubicin and fumonisin B1, IGF-I secretion was dramatically increased (≈ six-fold) (Fig. 5A) . To ascertain that IGF-I levels were not overestimated by interference with exogenous IGFBP-3, IGF-I was assayed also in cell-free medium 24 h after addition of IGFBP-3 (1000 ng/ml), being completely undetectable (data not shown).
Figure 5B shows that even IGF-I mRNA was significantly increased after 24 h treatment with IGFBP-3 compared with unstimulated cells.
The increase induced by IGFBP-3 suggests that IGF-I may act, in association to its major binding protein, as antiapoptotic and survival factor in endothelial cells. The increase in IGF-I release, observed when cells undergo apoptosis at a greater extent, that is, in IGFBP-3-treated cells with doxorubicin, may be explained as an attempt to escape from death by increasing one of the most powerful cell survival factors (3, 20) .
IGFBP-3 induces phosphorylation of the IGF-IR and activates PI3K/Akt and ERK
On the basis of the previous results showing an increase in IGF-I mRNA and protein secretion, we tried to determine whether IGFBP-3 protection in HUVEC was associated with an increase in signaling by the IGF-IR. Tyrosine phosphorylation of the IGF-IR β-subunit was analyzed by Western blot in serum-starved cells in the presence of IGFBP-3. As shown in Fig. 6A , phosphorylation increased at 10 min and peaked at 30 min after IGFBP-3 stimulation. As expected, addition of IGF-I induced the tyrosine phosphorylation of its receptor.
To determine if IGFBP-3 promoted cell survival in serum-free medium by acting through the IGF-IR signaling, apoptosis was assessed in the presence of IGFBP-3 and of the specific inhibitor of IGF-I receptor phosphorylation, tyrphostin AG1024 (21) . Tyrphostin AG1024 (1 µM) alone did not significantly increase apoptosis in serum deprived HUVEC. IGFBP-3 antiapoptotic effect in serum-deprived cells was completely abolished by tyrphostin AG1024 after 24 h incubation (Fig. 6B ). Notice that tyrphostin had similar effect on IGF-I protective action. Cell survival assay by MTT was also performed with similar results (data not shown).
IGFBP-3 was subsequently studied for activation of the antiapoptotic transduction pathways, PI3K/Akt and ERK, which signal downstream of the IGF-IR (20) . As shown in Fig. 6C , IGFBP-3 increased Akt phosphorylation at 30 min after stimulation in serum-free medium, with no variation at early time points (5 and 15 min). ERK1 and ERK2 phosphorylation rapidly increased by 5 min following incubation with IGFBP-3, being weakly detectable at 30 and 60 min (Fig.  6D ).
These results suggest that IGFBP-3 protection from apoptosis may depend on IGF-I increase through IGF-IR phosphorylation and activation of the survival pathways PI3K/Akt and ERK.
IGFBP-3 enhances motility of endothelial cells
Evidence shows that both IGF-I and S1P enhance endothelial cell motility (22, 19) . Thus, on the basis of our previous results, it was of interest to study whether IGFBP-3 could affect HUVEC migration. In serum-starved conditions, motility never exceeded 4 µm/h, whereas IGFBP-3 induced an immediate increase that remained significantly higher (≥6 µm/h), compared with control, throughout the observation period (Fig. 7A) . Figure 7B shows that fumonisin B1 acted on cell migration similarly to unstimulated cells (≈4 µm/h), whereas with IGFBP-3-induced motility, initially similar to fumonisin B1 alone, significantly increased in a time-dependent manner (≥5 µm/h), however, being lower than in cells without the ceramide synthase inhibitor. Compared with untreated cells or to cells with fumonisin B1, doxorubicin decreased HUVEC motility (<3 µm/h). IGFBP-3 showed no significant enhancement of motility when added to doxorubicin. This was likely because half of these cells were apoptotic ( Fig. 2B and C) ; however, even in this condition the migratory speed values were higher at almost every time points (≥3 µm/h) (Fig. 7C) . Figure 7D shows that fumonisin B1 increased motility of doxorubicin-treated cells, with speed values that were similar to cells without doxorubicin and in a time-dependent manner. IGFBP-3 significantly increased cell motility by fumonisin B1 over doxorubicin in a time-dependent manner, reaching speed values that were comparable to those obtained in the absence of the drug (≈5 µm/h). These results indicate that IGFBP-3 affects endothelial cell motility, increasing migration either alone or with fumonisin B1 and doxorubicin.
DISCUSSION
This study shows that IGFBP-3 has dual effects on survival and apoptosis in HUVEC. IGFBP-3 enhanced apoptosis induced by doxorubicin and increased endogenous ceramide. The inhibitor of ceramide synthase fumonisin B1 decreased apoptosis in doxorubicin-treated cells and IGFBP-3 surprisingly potentiated this effect with a concurrent decrease of ceramide levels. IGFBP-3 displayed also antiapoptotic effects in serum-starved cells. Indeed, we found that IGFBP-3: 1) decreased ceramide levels; 2) activated SK to generate S1P and increased SK1 mRNA, while DMS, a competitive inhibitor of SK, completely abrogated the protective effect of IGFBP-3; 3) induced IGF-I expression and strongly increased its release; 4) phosphorylated IGF-IR, Akt and ERK, whereas the inhibitor of IGF-IR tyrosine kinase activity, tyrphostin AG1024, abolished the protective effect of IGFBP-3; and 5) increased endothelial cell motility.
IGFBP-3 is known to exert antiproliferative effects in different cell types either by inhibiting IGF-I-mediated mitogenic effects or through mechanisms that are independent of IGF-I (4).
IGFBP-3 even induces apoptosis per se and potentiates the apoptotic effects of chemotherapeutic drugs and ceramide (23) (24) (25) . Furthermore, IGFBP-3 has been shown to act as a proliferative agent, either in an IGF-dependent or independent manner (26) (27) (28) . The precise mechanisms underlying the effects of IGFBP-3 remain poorly understood since a specific cell-surface receptor has not yet been characterized (29, 30) .
In the vasculature, IGFBP-3 has been shown to inhibit endothelial proliferation induced by vascular endothelial growth factor (VEGF) (31) but also to induce proliferation of primitive hematopoietic cells (32) . Moreover, IGFBP-3 is overexpressed during angiogenesis of the corpus luteum in humans (33) and in endothelial cells of mouse breast tumor vessels (34) , suggesting that it may regulate physiologic as well as pathologic angiogenesis.
We have previously shown that IGFBP-3 enhances apoptosis induced by doxorubicin in rat cardiac myocytes (5) . In the present study we made the novel observation that IGFBP-3 not only potentiates apoptosis induced by doxorubicin also in human endothelial cells but that it even increases intracellular ceramide content. We also show that IGFBP-3 alone has no growthinhibitory effect but it increases cell survival and reduces apoptosis triggered by serum deprivation, with a concomitant decrease in endogenous ceramide. To date, this is the first study showing that IGFBP-3 regulates intracellular ceramide levels in parallel with exerting different biologic effects in the same cell type.
In Hs578T breast cancer cells, IGFBP-3 has been shown to accentuate apoptosis induced by C2-ceramide, whereas no apoptotic effect was observed with IGFBP-3 alone (25) . In the normal breast epithelial cell line MCF-10A, IGFBP-3 reduced cell death induced by ceramide and showed differential IGF-independent effects on cell growth (35) . These studies indicated that IGFBP-3 inhibits or enhances cell growth and survival, depending on the cell line and exposure to death-inducing agents. However, an effect of IGFBP-3 on endogenous ceramide production had never been investigated. Doxorubicin is widely used in the treatment of cancer, and evidence has shown that either cytotoxic chemotherapy or antiangiogenic therapy are each dependent on endothelial cell apoptosis (36) . Ceramide, a key mediator of cell stress and apoptosis, is generated either from sphingomyelin (SM) by various SMases or de novo by serine palmitoyl transferase and ceramide synthase (6, (37) (38) . The de novo pathway can be stimulated by drugs in different cell types, including endothelial cells (10, 17, (39) (40) , and there is evidence that the doxorubicin analog daunorubicin triggers apoptosis and ceramide generation by activating ceramide synthase in leukemic cell lines. These effects were shown to be blocked by the specific ceramide synthase inhibitor fumonisin B1 (7). IGFBP-3, in turn, has been shown to mediate p53 signaling in fibroblasts in response to doxorubicin (41) and IGFBP-3 up-regulation sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells (24) . These studies are in agreement with our findings in HUVEC, showing that IGFBP-3 enhanced doxorubicin-induced apoptosis. Moreover, the ceramide analog C2-ceramide has been shown able to induce apoptosis in HUVEC (42) , suggesting that IGFBP-3 enhances apoptosis in doxorubicin-treated cells by increasing ceramide content. Doxorubicin is an amphiphillic drug; its transport over the plasma membrane occurs by passive diffusion, and there is evidence that the short chain sphingolipid Nhexanoyl-sphingomyelin potentiates doxorubicin cytotoxicity in endothelial cells by enhancing its cellular influx (43) . Moreover, glycosylation of ceramide by glucosylceramide synthase (GCS) has been shown to increase resistance to doxorubicin in breast cancer cells and GCS antisense oligonucleotides to overcome drug resistance by enhancing doxorubicin uptake and ceramide-induced apoptosis (44) . Therefore, it can be speculated that IGFBP-3 may increase doxorubicin uptake and apoptosis, altering membrane sphingolipids by increasing ceramide content but it would exert opposite effects when ceramide synthesis is inhibited by fumonisin B1. Further studies are needed to investigate this interesting alternative mechanism.
It has, however, to be emphasized that IGFBP-3, either in the presence of doxorubicin with fumonisin B1 or in serum-free medium with or without the inhibitor, decreases ceramide levels and acts as antiapoptotic factor. Our results strongly suggest that IGFBP-3 is, in fact, a survival factor for endothelial cells, except when in the presence of doxorubicin, which likely activates different signaling mechanisms. The dual effects of IGFBP-3 on ceramide production and biologic activity in HUVEC may be due to the paradigm of the ceramide/sphingosine-1-phosphate (S1P) rheostat as a mechanism for coordinately regulating proliferation and apoptosis through sphingolipids. While ceramide is often antiproliferative and proapoptotic, S1P has been implicated in cellular proliferation, cell survival, and in protection against apoptosis; in endothelial cells, it also stimulates migration and angiogenesis (16, 19) . In this study, we show that IGFBP-3 not only reduced ceramide and apoptosis in serum-starved cells but that it did so even in the presence of doxorubicin with fumonisin B1, the inhibitor of ceramide synthase that possibly moves the balance from ceramide to its metabolite S1P. S1P is generated by activation of SK, a lipid kinase that functions as an important signaling molecule and that is stimulated by different mitogenic and survival factors (19) . Importantly, we found that IGFBP-3 potently and rapidly activated SK, even inducing the expression of its antiapoptotic isoform SK1. Moreover, the SK inhibitor DMS completely blocked the IGFBP-3 antiapoptotic effect, suggesting that SK activation and S1P generation serve as signals for the IGFBP-3 survival effect in HUVEC.
On the other hand, another important aspect is that IGFBP-3 dramatically increased IGF-I release in cell conditioned medium and even increased IGF-I mRNA expression. IGF-I is a strong survival and antiapoptotic factor for many cell types (3, 20) , and it has been shown to induce endothelial cell migration and angiogenesis (22) . IGF-I binding to its receptor (IGF-IR) activates phosphorylation of the IGF-IR on tyrosine residues and subsequent phosphorylation of insulin receptor substrates (IRS). These reactions lead to activation of the PI3K/Akt and MEK/MAPK signaling pathways, which mediate many of the vascular effects of IGF-I, including endothelial cell survival and migration (45) . Herein, we show that IGFBP-3 stimulated IGF-IR tyrosine phosphorylation and even activated Akt and the MAPK family member ERK1/2. Furthermore, inhibition of IGF-IR phosphorylation with thyrphostin AG1024 not only abolished the antiapoptotic effect of IGF-I, but completely abrogated even the protective effect of IGFBP-3 against serum starvation-induced apoptosis. This result strongly suggests that the survival effect triggered by IGFBP-3 is mediated by the IGF-IR. Moreover, the increase in IGF-IR phosphorylation would indicate that IGF-I, strongly secreted under IGFBP-3 stimulation, is not bound to or sequestered by the added binding protein-3 and may thus exert its survival and antiapoptotic effects. In line with our results, there is evidence that IGFBP-3 activates a tyrosine phosphatase to inhibit IGF-I signaling in MCF-7 breast cancer cells (46) whereas, in MCF-10 mammary epithelial cells, IGFBP-3 enhances the proliferative effect of EGF, stimulates the tyrosine phosphorylation of the EGFR, and activates the p44/42 (ERK1/2) MAPK signaling pathway (27) .
It has been recently reported that VEGF stimulates SK1 to produce S1P (47) . In turn, S1P transactivates the receptor tyrosine kinases VEGFR2/Flk-1/KDR, platelet-derived growth factor β-receptor (PDGFβR), and epidermal growth factor receptor (EGFR) in HUVEC and in rat aortic vascular smooth muscle cells (48) . Moreover, IGF-I transactivates EGFR and induces angiogenesis via the up-regulation of VEGF mRNA (49, 50) . Thus, there is evidence for a crosstalk between IGF-I, vascular growth factors, and S1P in the regulation of endothelial cell fate.
Given that S1P potently stimulates endothelial cell motility (51) via VEGFR and CrkII phosphorylation, IGFBP-3 was finally studied for its ability to promote endothelial cell migration, which is important in many physiologic and pathologic processes, including inflammation, wound healing, and angiogenesis, as well as tumor growth and metastasis (36, 52) . We found that IGFBP-3 significantly increased endothelial cell motility, suggesting that S1P may be involved in this mechanism. Notably, CrkII phosphorylation is stimulated also by IGF-I to initiate IGF-IR downstream signaling, which provides further evidence that crosstalk occurs between S1P and IGF-I signaling.
In conclusion, we demonstrate that IGFBP-3 differentially regulates endothelial cell fate by acting on the ceramide and S1P signaling pathways. Moreover, IGFBP-3 survival effects appear to be mediated by the IGF-IR and involve the downstream survival signals Akt and ERK. Thus, IGFBP-3 has a novel role in the regulation of endothelial cell survival and we suggest the existence of an interplay between sphingolipids and the IGF-I system in the regulation of endothelial biologic outcome. Cumulatively, with the results shown in this study, the IGFBP-3-induced increase in cell motility may even suggest a role for this binding protein in promoting angiogenesis. Fig. 1 Page 17 of 24 (page number not for citation purposes) Figure 1 . Effect of IGFBP-3 on viability and apoptosis of endothelial cells exposed to serum-free medium in the presence or absence of doxorubicin. HUVEC were cultured in the presence of 20% fetal bovine serum (FBS), in serumfree medium (SF) with 0.1% BSA or in SF for 24 h with either 1000 ng/ml IGFBP-3 (BP-3) or 0.5 µM doxorubicin (Dox). A) Cell viability was assessed by the MTT assay. Data are expressed as the percentage relative to SF and are the means ± SE of 8 replicates within a single representative experiment that was repeated at least 3 times (*P<0.05). B) Apoptosis determined by FACS analysis after propidium iodide staining of nuclei. M1 represents percent of apoptotic cells in the Sub-G 1 peak. Results are the means ± SE of three experiments (*P<0.05, **P<0.01). C and D) Apoptotic cell death detected by Hoechst 33258 staining. Apoptosis was quantified under a fluorescence microscope by counting cells that showed clear chromatin condensation and nuclear fragmentation (indicated by arrows) compared with the total number of cells (magnification, ×400). Bar graphs show the means ± SE of duplicate determinations of 500 cells each of 3 independent experiments (*P<0.05). HUVEC in serum-free medium (SF) were pretreated with 1000 ng/ml IGFBP-3 (BP-3) for 1 h followed by 40 min incubation with fumonisin B1 (FB1) (100 µM) and 24 h with doxorubicin (Dox) (0.5 µM). The levels of endogenous ceramide were determined by the diacylclycerol kinase assay. A) Ceramide separated by TLC and detected by autoradiography. B) Quantitative analysis expressed as percent of ceramide in treated compared with untreated cells in serum-free medium (SF). Results are the mean ± SE of separate experiments repeated at least three times (*P<0.05, **P<0.001). measured in cytosolic fractions of HUVEC treated for the indicated times in serum-free medium with IGFBP-3 (1000 ng/ml). The formation of S1P was visualized by autoradiography (upper panel) and measured as described in "Materials and Methods". Graph results are the mean ± SE of three independent experiments (*P<0.05, **P<0.001). B) HUVEC were treated for the indicated times as for the SK activity assay, mRNA levels were determined by RT-PCR using specific primers for human SK1. Values from densitometric analysis were normalized to β-actin and reported as percent of the basal time point. Data represent the mean ± SE from three separate experiments (*P<0.001 for all time points vs. the basal time point). C) Inhibition of the antiapoptotic effect of IGFBP-3 by DMS (0.5 µM). HUVEC were incubated 40 min in the presence of DMS prior to addition of IGFBP-3. Apoptosis was quantified after 24 h by Hoechst 33258; values are the mean ± SE of 500 cells counted in duplicate from three independent experiments. (*P<0.05; **P<0.01). conditions with or without 1000 ng/ml IGFBP-3 (BP-3) (1 h preincubation), 100 µM fumonisin B1 (FB1) (40 min preincubation) and 0.5 µM doxorubicin (Dox). IGF-I levels were determined by RIA from concentrated conditioned medium as described in "Materials and Methods". Results shown are representative of experiments performed in triplicate from three separate experiments. B) IGF-I mRNA assessed by RT-PCR. Cells were cultured for 24 h in serum-free medium (SF) alone or in the presence of 1000 ng/ml IGFBP-3. Values from densitometric analysis were normalized to β-actin and reported as percent of SF. Results are the mean ± SE from three separate experiments (*P<0.001). antiapoptotic action by tyrphostin AG1024. HUVEC were incubated for the indicated time points with 1000 ng/ml IGFBP-3 (BP-3) under serum-starved conditions. A) Cell lysates were immunoprecipitated and analyzed by phosphotyrosine immunoblotting as described in "Materials and Methods". IGF-1R phosphorylation was examined in cells exposed to 15 nM IGF-I for 30 min. Equal loading of immunoprecipitated proteins was confirmed by reprobing immunoblots with IGF-IR β-subunit antibody. B) Apoptosis detected by Hoechst 33258 staining of cells cultured in serumfree medium (SF) for 24 h with either IGFBP-3 or IGF-I (15 nM) in the presence or absence of tyrphostin AG1024 (1 µM). Cells were incubated 30 min with AG1024 before the addition of IGFBP-3 or IGF-I. Data are the mean ± SE of three independent experiments. ns, not significant; *P < 0.001 for each condition AG1024 (+) vs. AG1024 (-). C) Akt phosphorylation evaluated by Western blot analysis on cell lysates obtained after IGFBP-3 stimulation at the indicated times. Equal protein loading was determined by reprobing with antibody to total Akt. D) ERK1/2 phosphorylation and total ERK analysis by Western blot on lysates from IGFBP-3 stimulated cells. In each panel, experiments were repeated with similar results at least three times. 7 . Motility of serum-deprived HUVEC measured as described in Materials and Methods. Cells were pretreated for 1 h with 1000 ng/ml IGFBP-3 (BP-3) followed by 100 µM fumonisin B1 (FB1) for 40 min and 0.5 µM doxorubicin (Dox) for 16 h. A) BP-3 compared with serum-free medium alone (P<0.001 at every time points). B) BP-3 with FB1 compared with FB1 alone (ns: not significant; *P<0.05; **P<0.01). C) BP-3 with Dox compared with Dox alone (not significant differences at every time points). D) Dox and FB1 in the presence or absence of BP-3 (ns: not significant; *P<0.05; **P<0.01). Results are expressed as means ± SE of three independent experiments.
